Table of Contents — Berberine Dossier 

Executive Snapshot
Supplement Name + Standardized Form
Organization Code (CV / DS / MSKS / NS / IS / ES) + Source Code

Origin & Historical Context
Origin and Source (Botanical/Compound Source + Plant Parts)
Geographic and Cultural Origins
Traditional Medicine Systems
Historical Use and Early Associations (Patterns, not claims)
Early Correlations / Observed Contexts

Pre-Clinical Biological Rationale (Mechanism-Level Education)
Core Pathways Overview
AMPK Activation (Energy Sensor)
Glucose Metabolism Modulation
Lipid & Cholesterol Regulation
Inflammation Signaling (NF-κB, COX-2, cytokines)
Gut Microbiota Axis (SCFA, bile acids, FXR)
Neurological Pathways (Monoamine oxidase, BDNF/CREB)
Cell Cycle & Apoptosis Pathways (MAPK, caspases)

Modern Clinical Context (Non-Claim)
Pharmaceutical Lineage & Drug-Class Comparisons (e.g., metformin-adjacent framing)
Natural vs. Synthetic / Salt Forms (e.g., HCl vs. fumarate)
Areas of Active Research (Metabolic, CV, hepatic, PCOS, neuro, oncology, renal)
Evidence Tier Summary (RCTs, systematic reviews/meta-analyses, trials registry)

Safety, Interactions & Quality Considerations
Known Safety Profile & Common Side Effects
Contraindications / Medication Interactions (as applicable)
Bioavailability & Dose Considerations (non-prescriptive)
Quality Risks (identity, adulteration, variability, contaminants)

Krafted Formulation Rationale (Krafted Difference)
Sourcing Standard
Standardization Targets
Purity Thresholds + Third-Party Testing Plan
Formulation Logic (why these extract grades + excipients)
6.5 Delivery Form Justification (capsule vs. powder/liquid)
6.6 Clinical Mindset + Future FDA Pathway Readiness

Who This Is For (Educational Framing)
Long-Term Health Optimization
Metabolic Resilience / Cardiovascular Upkeep
Clinically Curious Consumers (evidence > hype)

Regulatory Status & Transparency
Dietary Supplement Positioning + Structure/Function Language
Labeling Guardrails (no disease claims)
Manufacturing Standards (cGMP, COAs, lot traceability)
Documentation Discipline (internal QC/QA)

References

 


Dietary Supplement(s): Granular Berberine Hydrochloride (bark/root) Extract

Formula: Granular Berberine Hydrochloride Extract 97% (bark), Granular Berberine Hydrochloride Extract 8% (bark/root), Cellulose (vegetable capsule), MCC (microcrystalline cellulose), L-Leucine, Olive Oil.

Organ System Codes: MSKS/CV/NS/ES/IS
Origin and Source

Berberine is a compound with a deep history in traditional medicine systems, although much of the detailed scientific research and documentation of its mechanisms are recent.

• Botanical/Compound Source: Berberine is classified as a plant alkaloid. It is a metabolite of various Berberis species. For instance, one source refers to the study of the hydroalcoholic extract of Berberis Integerrima, and another mentions the effects of the plant alkaloid from Berberis Vulgaris.

• Physical Form: Historically, berberine has always been used in traditional medicine as a plant extract.

Geographic and Cultural Origins

• Traditional Medicine Systems: Berberine is explicitly associated with Traditional Chinese Medicine (TCM). The sources confirm that berberine has always been used in traditional medicine.

Historical Use and Early Associations

• Historical Use: Berberine has a long history of use in traditional medicine as a plant extract.

• Early Correlations (Patterns, not claims): Historically, berberine was likely associated with conditions related to its observed effects on metabolism. In modern scientific documentation, the antidiabetic properties of berberine were first recorded in 1986.

• Observed Population Outcomes/Contexts: While traditional uses are mentioned broadly, the clinical applications currently being studied align with its historical association with therapeutic effects. For example, its use in TCM has been documented in studies focused on type 2 diabetes. The widespread clinical investigation today focuses on its efficacy against metabolic diseases, including hyperlipidemia and insulin resistance.




Pre-Clinical Biological Rationale 

Berberine exerts its biological effects across multiple fundamental physiological pathways, primarily centered on regulating cellular energy status, inflammation, and gut-host interactions.

Core Biochemical and Cellular Pathways Influenced

Berberine is understood to influence several core systems responsible for maintaining metabolic balance (homeostasis):

1. AMPK Activation (Energy Sensor): The primary and most likely mechanism through which berberine regulates glucose uptake is the activation of 5-adenosine monophosphate kinase (AMPK). AMPK is a crucial energy sensor in the cell. By activating AMPK, berberine improves insulin sensitivity and increases the translocation of the glucose-4 transporter (GLUT4) into the plasma, which allows cells to take up glucose. Berberine can also increase Akt (protein kinase B) phosphorylation by activating AMPK, thereby activating this impaired signaling pathway in cases of insulin resistance.

2. Glucose Metabolism Modulation: Berberine supports glucose metabolism by stimulating glycolysis (the breakdown of glucose) via increased activity of glucokinases. Simultaneously, it inhibits processes that generate new glucose and fat, specifically gluconeogenesis and adipogenesis (fat cell creation) in the liver. Berberine may also reduce glucose transport across the intestinal epithelium by inhibiting glycosidase.

3. Lipid and Cholesterol Regulation: Berberine influences lipid metabolism by stimulating the AMPK-dependent adipose tissue triglyceride lipase. In cholesterol biosynthesis, it regulates the process through the increased phosphorylation of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), which is the rate-limiting enzyme in cholesterol production. It also inhibits adipocyte differentiation by reducing the expression of key receptors involved in lipid storage, such as the peroxisome proliferator-activated receptor (PPARγ) and the sterol element-binding protein-1 receptor (SREBP). Furthermore, it suppresses lipogenesis (fat synthesis) by inhibiting the SCAP/SREBP-1 pathway.

Relevance to Homeostasis, Metabolism, and Inflammation

• Metabolism and Homeostasis: Metabolic activity is the basic life activity that is fundamental for maintaining body functions. Berberine's broad actions on carbohydrate and lipid pathways position it as a modulator of overall metabolic homeostasis, particularly concerning energy imbalances associated with conditions like insulin resistance and obesity.

• Inflammation: Berberine exhibits anti-inflammatory properties by modulating key inflammatory signaling pathways. It curbs the gene transcription of inflammatory proteins such as interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF). It also halts the activation of the NF-κb signaling pathway and stalls the expression of cyclooxygenase 2 (COX-2) and prostaglandin E2. Chronic inflammation is a known component of metabolic syndrome pathogenesis.

• Gut Microbiota Axis: Due to its poor bioavailability, berberine’s action is highly likely related to affecting the composition of the gut microbiota, which in turn influences the host’s metabolic homeostasis. Berberine alters microbial pathways that regulate the production or transport of short-chain fatty acids (SCFA) and bile acids (BA). For instance, it modulates microbial bile acid metabolism and the intestinal Farnesoid X Receptor (FXR) signaling pathway, which controls lipid, glucose, and bile acid metabolism.

• Neurological Systems: Berberine acts as a neuroprotectant. It has been suggested to promote optimal mental health by increasing brain neurotransmitter levels, including dopamine, serotonin, and norepinephrine, through its ability to inhibit monoamine oxidase activity. Berberine also impacts pathways involving the brain-derived neurotrophic factor-cAMP response element binding protein pathway.

• Cell Life Cycles and Aging: Berberine is known for its activity in regulating cell processes relevant to aging and cell fate (like cancer pathways, but framed here mechanistically). It arrests human cells in the G1 phase at low concentrations and the G2/M phase at high concentrations. It activates apoptosis (programmed cell death) by up-regulating pro-apoptotic genes (CASP3, CASP8, CASP9, BIK, BAX, BAK1) and down-regulating anti-apoptotic genes (BCL2). It also modulates the MAPK (mitogen-activated protein kinase) signaling pathways (p38 MAPK, ERK1/2, JNK) which direct cell responses like apoptosis, proliferation, and differentiation.

Berberine's biological activity, therefore, is not limited to a single target but involves coordinating multiple central pathways—acting almost like a conductor tuning an orchestra of fundamental physiological systems involved in energy use and defense (inflammation/cell fate).


Modern Clinical Context 

Berberine has transitioned from a traditional herbal extract to a compound subject to intensive modern scientific scrutiny, particularly as a promising nutraceutical agent.

Pharmaceutical Lineage and Analog Distinctions

Berberine itself is a natural plant alkaloid that has traditionally been used as a plant extract.

• Modern Drug Comparisons: Due to its high efficacy and safety profile, berberine is frequently compared to metformin as an anti-diabetic agent. It may offer advantages in use, such as for patients who do not tolerate metformin therapy. Scientific reports suggest that berberine appears to produce significantly better results than metformin in blood glucose regulation and supersedes the benefits of rosiglitazone by improving fasting blood glucose levels. Furthermore, berberine may act similarly to anti-diabetic drugs like acarbose and metformin by modifying the gut microbiota.

• Synthetic/Natural Distinction: While the sources primarily discuss the natural alkaloid, a derivative, berberine fumarate (an organic acid salt), has been engineered, and it has been reported to exhibit better oral bioavailability.

Current Clinical Interest and Areas of Active Research

Berberine is receiving great interest due to its strong pharmacological activities. Clinical investigations are broad, focusing on its ability to modulate metabolic pathways and inflammatory processes.

Clinicians and researchers are actively studying berberine in relation to:

• Metabolic Diseases and Risk Factors: Berberine is extensively studied for its therapeutic effect on various metabolic disorders. Research focuses on its potential to improve obesity, hyperlipidemia, and insulin resistance. Specific factors studied include reducing triglycerides (TG), total cholesterol (TC), and low-density lipoprotein (LDL), while increasing high-density lipoprotein (HDL).

• Diabetes and Associated Conditions: Its antidiabetic activity is the most widely studied potential therapeutic application. This includes investigations into its effects on Type 2 Diabetes Mellitus (T2DM), prediabetes (impaired fasting glucose and impaired glucose tolerance), and preventing diabetic encephalopathy.

• Women's Health: Its efficacy is being investigated in women with Polycystic Ovary Syndrome (PCOS), particularly for reducing insulin resistance and improving ovulation.

• Cardiovascular and Liver Health: Berberine is studied in relation to preventing the development of atherosclerosis and other cardiovascular disorders, and its potential role in non-alcoholic fatty liver disease (NAFLD) and liver cirrhosis due to steatohepatitis.

• Oncology and Chemoprevention: The most important and widely studied property of berberine is its anticancer activity. Current trials are underway to study its role in the prevention of recurrence of colorectal adenoma in patients after polypectomy.

• Neurological/Psychiatric Support: Studies are being conducted on berberine as an adjuvant treatment to control weight gain and metabolic symptoms associated with antipsychotic therapy in patients with schizophrenia. It is also investigated for its neuroprotective and antidepressant effects.

• Inflammatory and Renal Conditions: Berberine is currently under investigation for chronic kidney disease and is studied for anti-inflammatory properties that may be relevant to conditions like rheumatoid arthritis.

Evidence Tier

Berberine's efficacy is largely evaluated through high-level clinical evidence, focusing primarily on metabolic health.

• RCTs (Randomized Clinical Trials): Berberine has been the subject of randomized controlled trials (RCTs) investigating its efficacy and safety alone for metabolic disorders. RCTs have been used to evaluate its effect on conditions like hypercholesterolemia, PCOS, and colorectal adenoma recurrence.

• Meta-analyses and Systematic Reviews (High Tier): There are systematic reviews and meta-analyses of RCTs evaluating the effect of berberine alone on metabolic disorders, drawing from multiple eligible documents. These analyses have evaluated key markers such as TG, TC, LDL, HDL, HOMA-IR, and Fasting Plasma Glucose (FPG). The analysis confirmed positive effects of berberine alone (when compared to standard control groups) on TG, TC, LDL, HOMA-IR, and FPG.

• Current Clinical Trials: Many ongoing clinical trials listed on clinical databases are studying berberine in relation to prediabetes, stable coronary artery disease, T2DM, non-alcoholic steatohepatitis, hypertension, and chronic kidney disease.

The high volume of meta-analyses and RCTs confirms that berberine is a biologically active compound with a strong and developing evidence tier for its influence on metabolic diseases.

Known Safety Profile and General Tolerability

Berberine generally exhibits a high safety profile.

• Side Effects and Tolerability: The side effects of berberine are considered minimal.

• Common Issues: The side effects that do occur mainly affect the digestive system.

Studies often assess the efficacy and safety of berberine, finding positive outcomes when it is administered alone for metabolic disorders. Furthermore, when berberine is used in combination with other nutraceuticals, such as red yeast rice and policosanol, the combination has been shown to be safe and well-tolerated.

Poor Bioavailability and Dose Considerations

While not explicitly a "high dose issue" in terms of toxicity described here, a key characteristic of berberine impacting its use and effectiveness is its poor bioavailability after oral administration.

• Only nanomolar plasma concentrations can be achieved in both humans and animals following oral intake.

• This low bioavailability is thought to be the reason why a significant part of its effect is related to its interaction with the gut microbiota.

Quality and Standardization Considerations

The sources highlight the form of berberine used in research and the existence of specific derivatives, which speaks to the need for standardization:

• Variability in Active Constituents (Forms): The material you provided indicates two different extracts: Granular Berberine Hydrochloride Extract 97% (bark) and Granular Berberine Hydrochloride Extract 8% (bark/root). These suggest a difference in both purity (97% vs. 8% berberine) and source material (bark vs. bark/root), indicating that the concentration of the active alkaloid can vary greatly depending on the standardization and plant part used.

• Engineered Derivative: A key issue related to bioavailability has led to the development of derivatives. For instance, berberine fumarate (an organic acid derivative) has been synthesized and reported to have better oral bioavailability than the standard form. This suggests that the form of the salt (like the "Berberine Hydrochloride" mentioned in your formula) is important for clinical relevance and absorption.

Our Sourcing Standard

This formulation is built on verified botanical alkaloid sourcing, not commodity-grade berberine powders. All berberine inputs are derived from authenticated Berberis species, with documented plant part origin (bark and/or bark–root) and full supplier traceability. Each supplier is qualified through documentation review and lot-specific Certificates of Analysis (COAs), ensuring botanical identity, alkaloid content, and absence of adulteration.

This approach reflects a foundational principle: berberine is not interchangeable across sources or forms, and biological relevance depends on controlled chemical composition.

Standardization Targets

Rather than relying on a single purity grade, this formulation intentionally combines:

  • Granular Berberine Hydrochloride Extract (97%) — providing a precise, analytically robust alkaloid source

  • Granular Berberine Hydrochloride Extract (8%) — contributing a broader phytochemical context derived from bark/root material

This dual-extract strategy reflects the reality of published research, where berberine has been studied both as a highly purified alkaloid and within more complex botanical matrices. Standardization targets are defined at the alkaloid level, ensuring consistent berberine exposure per serving while acknowledging that biological effects may arise from both concentration and context.

Purity Thresholds

Each production lot is required to meet conservative purity specifications aligned with pharmaceutical-adjacent expectations, including:

  • Heavy metals panel (ICP-MS)

  • Microbial limits

  • Residual solvents (where applicable to extraction)

  • Identity confirmation of berberine hydrochloride salt form

These thresholds are designed not merely for compliance, but to minimize biological noise and support reproducibility across batches.

Third-Party Testing

Independent third-party laboratories verify:

  • Botanical identity

  • Berberine content (quantitative assay)

  • Absence of contaminants

Validated analytical methods (commonly HPLC or UHPLC) are used to confirm alkaloid concentration, ensuring that labeled content reflects true chemical composition rather than nominal input weights.

Formulation Logic

Berberine’s biological activity is notable for its multi-pathway engagement—including AMPK signaling, lipid metabolism, inflammatory cascades, and gut–host interactions—paired with poor systemic bioavailability following oral administration. This formulation is intentionally designed with that reality in mind.

By combining different standardized extract grades and incorporating excipients such as microcrystalline cellulose, L-leucine, and olive oil, the formulation prioritizes:

  • Content uniformity

  • Flow and capsule consistency

  • Reproducible delivery rather than maximal absorption claims

The goal is not to engineer pharmacokinetic enhancement prematurely, but to establish a stable, measurable baseline formulation suitable for future optimization.

Dose Rationale 

The serving size is designed to deliver a consistent, quantifiable berberine alkaloid dose, reflecting ranges commonly evaluated in human clinical research. This avoids a widespread market issue in which products list berberine-containing plants without verifying alkaloid exposure.

Importantly, this dose is framed as biologically informed, not prescriptive—intended to support metabolic homeostasis pathways studied in the literature rather than to imply treatment or disease modification.

Delivery Form Justification

A vegetable capsule format was selected to support:

  • Accurate dose control

  • Protection of hygroscopic alkaloids

  • Scalability and batch consistency

Capsules allow precise standardization and straightforward analytical verification, making them preferable to powders or liquids at this stage of development.

Clinical Mindset

This formulation is built with a clinical research mindset, not a marketing one. Decisions around sourcing, standardization, and testing are aligned with how compounds are evaluated in randomized trials and meta-analyses—not how supplements are typically commoditized.

The formulation deliberately avoids excessive complexity, proprietary blends, or unverifiable enhancements, prioritizing clarity, traceability, and interpretability.

Designed with Future FDA Pathways in Mind

While currently positioned as a dietary supplement, this formulation is structured to be:

  • Measurable (defined alkaloid content)

  • Reproducible (lot-to-lot consistency)

  • Scalable (CMC-ready inputs and documentation)

These attributes support long-term translational potential, including alignment with future botanical drug development frameworks should regulatory strategy evolve.


Who Berberine Is For 

Berberine is a subject of great interest in modern research and is particularly relevant for individuals focused on optimizing long-term health, metabolic function, and cardiovascular protection, given the strong evidence base surrounding its effects on metabolic disorders.

Individuals Interested in Long-Term Health Optimization

For individuals prioritizing long-term health optimization and seeking comprehensive support, berberine addresses several fundamental health areas:

• Metabolic Homeostasis: Berberine supports metabolic activity, which is the basic life activity necessary for maintaining body functions. It acts as a nutraceutical that positively contributes to regulating key metabolic parameters.

• Inflammation: Berberine exhibits an anti-inflammatory property by stalling the expression of pro-inflammatory mediators like cyclooxygenase 2 (COX-2) and prostaglandin E2. Chronic inflammation is a component of many diseases, making anti-inflammatory effects key for long-term health.

• Gut Health: Due to its poor absorption, berberine is highly likely to act by affecting the composition of the gut microbiota, which is associated with the regulation of the host’s health and metabolism.

Focused on Aging Well, Metabolic Resilience, or Cardiovascular Upkeep

Berberine is actively investigated for its influence on the major factors associated with metabolic syndrome, a cluster of conditions linked to aging and chronic disease risk:

• Metabolic Resilience (Insulin & Glucose Control): Berberine’s antidiabetic activity is its best-studied potential therapeutic application. It is studied for its ability to reduce insulin resistance and improve parameters such as fasting plasma glucose (FPG) and glycosylated hemoglobin. This is crucial because insulin resistance and obesity are key sources of metabolic syndrome pathogenesis, concerns that affect a growing group of people. Berberine is also studied for prediabetes (impaired fasting glucose and impaired glucose tolerance).

• Cardiovascular Upkeep (Lipid Management): Berberine is scientifically proven to help reduce hyperlipidemia, a primary cardiovascular risk factor. Systematic reviews confirm that berberine alone is effective at reducing unhealthy lipids: total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL), while increasing the beneficial high-density lipoprotein (HDL). It is also studied in relation to preventing the development of atherosclerosis and other cardiovascular disorders.

• Whole-Body Consequences of Metabolic Disorders: Berberine is also studied in relation to conditions that result from metabolic syndrome, such as non-alcoholic fatty liver disease (NAFLD) and diabetic encephalopathy. Its benefits in improving metabolic parameters in women with Polycystic Ovary Syndrome (PCOS) by reducing insulin resistance and improving ovulation are also noted.

Clinically Curious Consumers Who Value Evidence Over Hype

Berberine appeals to consumers who prioritize evidence-based supplementation because its effects are primarily supported by high-quality clinical research:

• High-Tier Evidence: The efficacy and safety of berberine have been evaluated in numerous systematic reviews and meta-analyses of randomized clinical trials (RCTs) focusing on its effect alone on metabolic disorders.

• Defined Clinical Contexts: Current active clinical trials are studying berberine's role in specific, complex, and serious conditions, including the prevention of recurrence of colorectal adenoma in high-risk patients, chronic kidney disease, and managing metabolic symptoms in patients with schizophrenia receiving antipsychotic therapy. The volume of research confirms that it is an alkaloid with strong pharmacological activities that are receiving great interest.


References

  1. An Y., Sun Z., Zhang Y., Liu B., Guan Y., Lu M. (2014). The Use of Berberine for Women with Polycystic Ovary Syndrome Undergoing IVF Treatment. Clin. Endocrinol. 80 (3), 425–431. doi: 10.1111/cen.12294.,

  2. Belwal T., Bisht A., Devkota H. P., Ullah H., Khan H., Bhatt I. D., et al. (2020). Phytopharmacology and Clinical Updates of Berberis Species Against Diabetes and Other Metabolic Diseases. Front. Pharmacol. 11, 41. 10.3389/fphar.2020.00041.

  3. Chang W., Zhang M., Li J., Meng Z., Wei S., Du H., Chen L., Hatch G.M. Berberine Improves Insulin Resistance in Cardiomyocytes via Activation of 5′-Adenosine Monophosphate-Activated Protein Kinase. Metabolism. 2013;62:1159–1167. doi: 10.1016/j.metabol.2013.02.007.

  4. Chen Y.-X., Gao Q.-Y., Zou T.-H., Wang B.-M., Liu S.-D., Sheng J.-Q., Ren J.-L., Zou X.-P., Liu Z.-J., Song Y.-Y., et al. Berberine versus Placebo for the Prevention of Recurrence of Colorectal Adenoma: A Multicentre, Double-Blinded, Randomised Controlled Study. Lancet Gastroenterol. Hepatol. 2020;5:267–275. doi: 10.1016/S2468-1253(19)30409-1.

  5. Chidambara Murthy K.N., Jayaprakasha G.K., Patil B.S. The Natural Alkaloid Berberine Targets Multiple Pathways to Induce Cell Death in Cultured Human Colon Cancer Cells. Eur. J. Pharmacol. 2012;688:14–21. doi: 10.1016/j.ejphar.2012.05.004.

  6. Cereda E., Cappello S., Caraccia M., Turri A., Masi S., Nappi R., Caccialanza R. SUN-PO004: Nutraceutical Intervention with Berberine, Chlorogenic Acid and Tocotrienols for Menopause-Associated Dyslipidemia: A Pilot, Single-ARM Trial. Clin. Nutr. 2019;38:S60. doi: 10.1016/S0261-5614(19)32641-X.

  7. Cui H.-X., Hu Y.-N., Li J.-W., Yuan K., Guo Y. Preparation and Evaluation of Antidiabetic Agents of Berberine Organic Acid Salts for Enhancing the Bioavailability. Molecules. 2019;24:103. doi: 10.3390/molecules24010103.

  8. Dahlberg C.J., Ou J.J., Babish J.G., Lamb J.J., Eliason S., Brabazon H., Gao W., Kaadige M.R., Tripp M.L. A 13-Week Low Glycemic Load Diet and Lifestyle Modification Program Combining Low Glycemic Load Protein Shakes and Targeted Nutraceuticals Improved Weight Loss and Cardio-Metabolic Risk Factors. Can. J. Physiol. Pharmacol. 2017;95:1414–1425. doi: 10.1139/cjpp-2016-0704.

  9. Derosa G., D’Angelo A., Vanelli A., Maffioli P. An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia. Diabetes Metab. Syndr. Obes. 2020;13:653–661. doi: 10.2147/DMSO.S232791.,

  10. Fan J., Zhang K., Jin Y., Li B., Gao S., Zhu J., Cui R. Pharmacological Effects of Berberine on Mood Disorders. J. Cell. Mol. Med. 2019;23:21–28. doi: 10.1111/jcmm.13930.

  11. Farooqi A.A., Qureshi M.Z., Khalid S., Attar R., Martinelli C., Sabitaliyevich U.Y., Nurmurzayevich S.B., Taverna S., Poltronieri P., Xu B. Regulation of Cell Signaling Pathways by Berberine in Different Cancers: Searching for Missing Pieces of an Incomplete Jig-Saw Puzzle for an Effective Cancer Therapy. Cancers. 2019;11:478. doi: 10.3390/cancers11040478.

  12. Gonnelli S., Caffarelli C., Stolakis K., Cuda C., Giordano N., Nuti R. Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols, and Berberine) in Patients with Low-Moderate Risk Hypercholesterolemia: A Double-Blind, Placebo-Controlled Study. Curr. Ther. Res. 2015;77:1–6. doi: 10.1016/j.curtheres.2014.07.003.

  13. Habtemariam S. Berberine Pharmacology and the Gut Microbiota: A Hidden Therapeutic Link. Pharmacol. Res. 2020;155:104722. doi: 10.1016/j.phrs.2020.104722.

  14. Home-ClinicalTrials.Gov. [(accessed on 22 January 2022)]; Available online: https://clinicaltrials.gov/.,

  15. Hu Y., Davies G.E. Berberine Inhibits Adipogenesis in High-Fat Diet-Induced Obesity Mice. Fitoterapia. 2010;81:358–366. doi: 10.1016/j.fitote.2009.10.010.

  16. Imanshahidi M., Hosseinzadeh H. Pharmacological and Therapeutic Effects of Berberis Vulgaris and Its Active Constituent, Berberine. Phytother. Res. 2008;22:999–1012. doi: 10.1002/ptr.2399.

  17. Ko B.-S., Choi S.B., Park S.K., Jang J.S., Kim Y.E., Park S. Insulin Sensitizing and Insulinotropic Action of Berberine from Cortidis Rhizoma. Biol. Pharm. Bull. 2005;28:1431–1437. doi: 10.1248/bpb.28.1431.

  18. Kong L.D., Cheng C.H., Tan R.X. Monoamine Oxidase Inhibitors from Rhizoma of Coptis Chinensis. Planta Med. 2001;67:74–76. doi: 10.1055/s-2001-10874.

  19. Kumar A., Ekavali, Mishra J., Chopra K., Dhull D. K. (2016). Possible Role of P-Glycoprotein in the Neuroprotective Mechanism of Berberine in Intracerebroventricular Streptozotocin-Induced Cognitive Dysfunction. Psychopharmacol. 233 (1), 137–152. 10.1007/s00213-015-4095-7.

  20. Lan J., Zhao Y., Dong F., Yan Z., Zheng W., Fan J., Sun G. Meta-Analysis of the Effect and Safety of Berberine in the Treatment of Type 2 Diabetes Mellitus, Hyperlipemia and Hypertension. J. Ethnopharmacol. 2015;161:69–81. doi: 10.1016/j.jep.2014.09.049.

  21. Li H.-L., Wu H., Zhang B.-B., Shi H.-L., Wu X.-J. MAPK Pathways Are Involved in the Inhibitory Effect of Berberine Hydrochloride on Gastric Cancer MGC 803 Cell Proliferation and IL-8 Secretion in Vitro and in Vivo. Mol. Med. Rep. 2016;14:1430–1438. doi: 10.3892/mmr.2016.5361.

  22. Li M., Liu Y., Qiu Y., Zhang J., Zhang Y., Zhao Y., Jia Q., Li J. The Effect of Berberine Adjunctive Treatment on Glycolipid Metabolism in Patients with Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Psychiatry Res. 2021;300:113899. doi: 10.1016/j.psychres.2021.113899.

  23. Lin X., Zhang N. Berberine: Pathways to Protect Neurons. Phytother. Res. 2018;32:1501–1510. doi: 10.1002/ptr.6107.

  24. Liu D., Meng X., Wu D., Qiu Z., Luo H. A Natural Isoquinoline Alkaloid With Antitumor Activity: Studies of the Biological Activities of Berberine. Front. Pharmacol. 2019;10:9. doi: 10.3389/fphar.2019.00009.

  25. Liu Y., Hua W., Li Y., Xian X., Zhao Z., Liu C., Zou J., Li J., Fang X., Zhu Y. Berberine Suppresses Colon Cancer Cell Proliferation by Inhibiting the SCAP/SREBP-1 Signaling Pathway-Mediated Lipogenesis. Biochem. Pharmacol. 2020;174:113776. doi: 10.1016/j.bcp.2019.113776.

  26. Lou T., Zhang Z., Xi Z., Liu K., Li L., Liu B., et al. (2011). Berberine Inhibits Inflammatory Response and Ameliorates Insulin Resistance in Hepatocytes. Inflammation 34 (6), 659–667. 10.1007/s10753-010-9276-2.

  27. Lynch C.J., Adams S.H. Branched-Chain Amino Acids in Metabolic Signalling and Insulin Resistance. Nat. Rev. Endocrinol. 2014;10:723–736. doi: 10.1038/nrendo.2014.171.

  28. Neag M. A., Mocan A., Echeverria J., Pop R. M., Bocsan C. I., Crisan G., et al. (2018). Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Front. pharmacol. 9, 557. 10.3389/fphar.2018.00557.

  29. Och A, Och M, Nowak R, Podgórska D, Podgórski R. Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease. Molecules. 2022 Feb 17;27(4):1351. doi: 10.3390/molecules27041351.,,

  30. Och A., Zalewski D., Komsta Ł., Kołodziej P., Kocki J., Bogucka-Kocka A. Cytotoxic and Proapoptotic Activity of Sanguinarine, Berberine, and Extracts of Chelidonium majus L. and Berberis Thunbergii DC. toward Hematopoietic Cancer Cell Lines. Toxins. 2019;11:485. doi: 10.3390/toxins11090485.

  31. Palmieri A., Scapoli L., Iapichino A., Mercolini L., Mandrone M., Poli F., Giannì A.B., Baserga C., Martinelli M. Berberine and Tinospora cordifolia Exert a Potential Anticancer Effect on Colon Cancer Cells by Acting on Specific Pathways. Int. J. Immunopathol. Pharmacol. 2019;33 doi: 10.1177/2058738419855567.

  32. Spigoni V., Aldigeri R., Antonini M., Micheli M.M., Fantuzzi F., Fratter A., Pellizzato M., Derlindati E., Zavaroni I., Bonadonna R.C., et al. Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study. Int. J. Mol. Sci. 2017;18:1498. doi: 10.3390/ijms18071498.

  33. Tian Y., Cai J., Gui W., Nichols R.G., Koo I., Zhang J., Anitha M., Patterson A.D. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation. Drug Metab. Dispos. 2019;47:86–93. doi: 10.1124/dmd.118.083691.

  34. Wang H., Zhu C., Ying Y., Luo L., Huang D., Luo Z. Metformin and Berberine, Two Versatile Drugs in Treatment of Common Metabolic Diseases. Oncotarget. 2017;9:10135–10146. doi: 10.18632/oncotarget.20807.

  35. Wang L., Peng L., Wei G., Ge H. Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016;36:681–684.

  36. Wang Y., Zhou M., Shang D. Berberine Inhibits Human Gastric Cancer Cell Growth via Deactivation of P38/JNK Pathway, Induction of Mitochondrial-Mediated Apoptosis, Caspase Activation and NF-ΚB Inhibition. J. Balk. Union Oncol. 2020;25:314–318.

  37. Wang Y., Shou J.-W., Li X.-Y., Zhao Z.-X., Fu J., He C.-Y., Feng R., Ma C., Wen B.-Y., Guo F., et al. Berberine-Induced Bioactive Metabolites of the Gut Microbiota Improve Energy Metabolism. Metabolism. 2017;70:72–84. doi: 10.1016/j.metabol.2017.02.003.

  38. Wang Y., Zidichouski J.A. Update on the Benefits and Mechanisms of Action of the Bioactive Vegetal Alkaloid Berberine on Lipid Metabolism and Homeostasis. Cholesterol. 2018;2018:7173920. doi: 10.1155/2018/7173920.

  39. Yan H.-M., Xia M.-F., Wang Y., Chang X.-X., Yao X.-Z., Rao S.-X., Zeng M.-S., Tu Y.-F., Feng R., Jia W.-P., et al. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE. 2015;10:e0134172. doi: 10.1371/journal.pone.0134172.

  40. Yan K., Zhang C., Feng J., Hou L., Yan L., Zhou Z., Liu Z., Liu C., Fan Y., Zheng B., et al. Induction of G1 Cell Cycle Arrest and Apoptosis by Berberine in Bladder Cancer Cells. Eur. J. Pharmacol. 2011;661:1–7. doi: 10.1016/j.ejphar.2011.04.021.

  41. Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, Chen Q. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2021 Apr 26;12:653887. doi: 10.3389/fphar.2021.653887.

  42. Yin J., Xing H., Ye J. Efficacy of Berberine in Patients with Type 2 Diabetes Mellitus. Metabolism. 2008;57:712–717. doi: 10.1016/j.metabol.2008.01.013.

  43. Zhang L.-S., Zhang J.-H., Feng R., Jin X.-Y., Yang F.-W., Ji Z.-C., Zhao M.-Y., Zhang M.-Y., Zhang B.-L., Li X.-M. Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am. J. Chin. Med. 2019;47:751–767. doi: 10.1142/S0192415X19500393.

  44. Zhang X., Zhao Y., Xu J., Xue Z., Zhang M., Pang X., Zhang X., Zhao L. Modulation of Gut Microbiota by Berberine and Metformin during the Treatment of High-Fat Diet-Induced Obesity in Rats. Sci. Rep. 2015;5:14405. doi: 10.1038/srep14405.

  45. Zhang Y., Li X., Zou D., Liu W., Yang J., Zhu N., et al. (2008). Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine. J. Clin. Endocrinol. Metab. 93 (7), 2559–2565. 10.1210/jc.2007-2404.

  46. Zhang Y., Sun J., Zhang Y.-J., Chai Q.-Y., Zhang K., Ma H.-L., Wu X.-K., Liu J.-P. The Effect of Berberine on Insulin Resistance in Women with Polycystic Ovary Syndrome: Detailed Statistical Analysis Plan (SAP) for a Multicenter Randomized Controlled Trial. Trials. 2016;17:512. doi: 10.1186/s13063-016-1633-5.

  47. Zhao J.V., Yeung W.-F., Chan Y.-H., Vackova D., Leung J.Y.Y., Ip D.K.M., Zhao J., Ho W.-K., Tse H.-F., Schooling C.M. Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial. Nutrients. 2021;13:2550. doi: 10.3390/nu13082550.

  48. Zheng F., Tang Q., Wu J., Zhao S., Liang Z., Li L., Wu W., Hann S. P38α MAPK-Mediated Induction and Interaction of FOXO3a and P53 Contribute to the Inhibited-Growth and Induced-Apoptosis of Human Lung Adenocarcinoma Cells by Berberine. J. Exp. Clin. Cancer Res. 2014;33:36. doi: 10.1186/1756-9966-33-36.